1. PepGen Inc. shareholders can join a class action lawsuit. 2. Allegations of misleading statements about PGN-EDO51's effectiveness. 3. Potential halt of CONNECT2 study raises regulatory concerns. 4. Deadline for class action registration is August 8, 2025. 5. Investors claim artificial inflation of PEPG's stock price.
The class action suit involves allegations that could severely impact investor confidence. Historically, similar lawsuits have led to significant drops in stock prices, e.g.,Valeant Pharmaceuticals after misleading statements regarding revenues.
The lawsuit directly challenges PEPG's core product efficacy, impacting future sales and trust. Investors are likely to react sharply to these allegations, significantly affecting stock value.
The ongoing litigation and associated uncertainties can impact PEPG for years. Past cases have shown that it can take a prolonged period for companies to recover from class action claims.
NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).
Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=156352&from=4
March 7, 2024 to March 3, 2025
The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company's lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times.
August 8, 2025. Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=156352&from=4
Once you register as a shareholder who purchased shares of PEPG during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 8, 2025. There is no cost or obligation to you to participate in this case.
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903
SOURCE The Gross Law Firm